AOK Sachsen - Anhalt
Germany · 380 open tenders · 171 documented awards
Current tenders
Medicinal products with the active substance treprostinil (ATC: B01AC21)
Deadline 30 Aug · 11 days left
Medicinal products with the active substance Lipegfilgrastim (ATC: L03AA14)
Deadline 30 Aug · 11 days left
Medicinal products containing the active substance Erythropoietin (ATC: B03XA01 - in strengths exceeding 10,000 IU per unit dose)
Deadline 30 Aug · 11 days left
Pharmaceuticals with the active ingredient Erythropoietin (ATC: B03XA01 - in the strength up to 10,000 IU per unit dose)
Deadline 30 Aug · 11 days left
Germany – Pharmaceuticals – Pharmaceuticals containing the active substance erythropoietin (ATC: B03XA01 - in the potency up to 10,000 IU per unit dose)
Deadline 31 Aug · 11 days left
Germany – Pharmaceuticals – Pharmaceuticals with the active substance Treprostinil (ATC: B01AC21)
Deadline 31 Aug · 11 days left
Germany – Medicinal Products – Medicinal Products Containing the Active Substance Erythropoietin (ATC: B03XA01 - in Strengths Exceeding 10,000 IU per Dosage Unit)
Deadline 31 Aug · 11 days left
Medicinal products with the active substance Lipegfilgrastim (ATC: L03AA14)
Deadline 31 Aug · 11 days left
Medicinal products containing the active substance Erythropoietin (ATC: B03XA01 - in the strength up to 10,000 IU per dose unit)
Deadline 31 Aug · 11 days left
Medicinal products with the active substance Treprostinil (ATC: B01AC21)
Deadline 31 Aug · 11 days left
Medicinal products containing the active substance erythropoietin (ATC: B03XA01 - in strengths above 10,000 IU per unit dose)
Deadline 31 Aug · 11 days left
Germany – Medicines – Medicines containing the active substance Lipegfilgrastim (ATC: L03AA14)
Deadline 31 Aug · 11 days left
Medicinal products containing the active substance bosutinib (ATC: L01EA04)
Deadline 29 Sept · 41 days left
Medicinal products containing the active substance Bosutinib (ATC: L01EA04)
Deadline 30 Sept · 41 days left
Germany – Medicinal products – Medicinal products containing the active substance Bosutinib (ATC: L01EA04)
Deadline 30 Sept · 41 days left
Medicinal product with the active ingredient rituximab - in the pharmaceutical form infusion solution concentrate (ATC: L01FA01)
Deadline 30 Oct · 72 days left
Medicinal products with the active ingredient combination brimonidine and timolol (ATC: S01ED67)
Deadline 30 Oct · 72 days left
Medicinal product with the active ingredient combination formoterol and beclomethasone (ATC: R03AK08 - in the strength 200/6 micrograms)
Deadline 30 Oct · 72 days left
Medicines containing the active substance sevelamer hydrochloride (ATC: V03AE02)
Deadline 30 Oct · 72 days left
Medicinal product with the active substance Bimekizumab (ATC: L04AC21)
Deadline 30 Oct · 72 days left
Medicinal product with the active substance Bimekizumab (ATC: L04AC21)
Deadline 31 Oct · 72 days left
Medicinal product with the active substance Rituximab - in the pharmaceutical form infusion solution concentrate (ATC: L01FA01)
Deadline 31 Oct · 72 days left
Germany – Medicinal Products – Medicinal Products Containing the Active Ingredient Combination Brinzolamide and Timolol (ATC: S01ED67)
Deadline 31 Oct · 72 days left
Germany – Medicinal Products – Medicinal Products with the Active Ingredient Combination Formoterol and Beclomethasone (ATC: R03AK08 - in the Strength 200/6 Micrograms)
Deadline 31 Oct · 72 days left
Germany – Medicinal Products – Medicinal Products Containing the Active Substance Bimekizumab (ATC: L04AC21)
Deadline 31 Oct · 72 days left
Medicine with the active substance Sevelamer hydrochloride (ATC: V03AE02)
Deadline 31 Oct · 72 days left
Germany – Pharmaceuticals – Pharmaceuticals with the active substance Rituximab - in the dosage form infusion solution concentrate (ATC: L01FA01)
Deadline 31 Oct · 72 days left
Medicinal product with the active ingredient combination brinzolamide and timolol (ATC: S01ED67)
Deadline 31 Oct · 72 days left
Germany – Pharmaceuticals – Pharmaceuticals containing the active substance sevelamer hydrochloride (ATC: V03AE02)
Deadline 31 Oct · 72 days left
Medicinal product with the active ingredient combination Formoterol and Beclometasone (ATC: R03AK08 - in the strength 200/6 micrograms)
Deadline 31 Oct · 72 days left
Purchasing rhythm
Awards per year — who knows the rhythm prepares before the notice appears.
201836
201985
202092
2021114
2022110
2023198
2024339
2025460
2026191
Who has won here before
| Company | Awards | Period |
|---|---|---|
| GlaxoSmithKline GmbH & Co. KG · München | 5 | 2012–2026 |
| Novartis Pharma GmbH · Nürnberg | 5 | 2013–2026 |
| PIK AG | 5 | 2025 |
| Städtische Werke Magdeburg GmbH & Co. KG | 4 | 2025 |
| RpDoc Solutions GmbH · Saarbrücken | 4 | 2026 |
| Pfizer Pharma GmbH · Berlin | 3 | 2023–2025 |
| Janssen-Cilag GmbH · Neuss | 3 | 2012–2023 |
| TEVA GmbH Deutschland · Ulm | 3 | 2015–2016 |
| GlaxoSmithKline GmbH & Co.KG · München | 3 | 2016–2018 |
| Bayer Vital GmbH · Leverkusen | 3 | 2014–2023 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.